Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan

Neurosurgery

Volumn 69, Issue 6, 2011, Pages 1272-1279

  Bruce, Jeffrey N ^a   Fine, Robert L ^a   Canoll, Peter ^a   Yun, Jonathan ^a   Kennedy, Benjamin C ^a   Rosenfeld, Steven S ^a   Sands, Stephen A ^a   Surapaneni, Krishna ^a   Lai, Rose ^a   Yanes, Candix L ^a   Bagiella, Emilia ^a   Delapaz, Robert L ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Clinical trial; Glioblastoma; Glioma; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARM WEAKNESS; ARTICLE; BACKACHE; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COGNITIVE DEFECT; CONVECTION ENHANCED DELIVERY; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; GANGRENE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HUMAN; LEG PAIN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; PARIETAL SYNDROME; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; THERMODYNAMICS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ATTENTION; CONVECTION; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REACTION TIME; SUPRATENTORIAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TOPOISOMERASE I INHIBITORS; TOPOTECAN; YOUNG ADULT;

EID: 80955137530     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3182233e24     Document Type: Article

References (32)

1. Barker FG II, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42(4):709-720.
2. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076-2080. (Pubitemid 24092045)
3. Broaddus WC, Prabhu SS, Gillies GT, et al. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg. 1998;88(4):734-742. (Pubitemid 28145218)
4. Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res. 2000;856(1-2):281-290. (Pubitemid 30085537)
5. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery. 2000;47(6):1391-1398.
6. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH. Focal delivery during direct infusion to brain: Role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol. 1999;277(4)(pt 2):R1218-R1229. (Pubitemid 29525980)
7. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010;6(1):117-125.
8. Rainov NG, Gorbatyuk K, Heidecke V. Clinical trials with intracerebral convection- enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials. 2008;3(1):2-9. (Pubitemid 351267022)
9. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg. 2004;100(3):472-479. (Pubitemid 38269075)
10. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12(8):871-881.
11. Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery. 2000;46(3):683-691. (Pubitemid 30146156)
12. Burris HA III. Topotecan: Incorporating It Into the treatment of solid tumors. Oncologist. 1998;3(1):1-3.
13. Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T, Nagao S. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol. 1993;53(2):97-103. (Pubitemid 23164595)
14. Friedman HS, Kerby T, Fields S, et al. Topotecan treatment of adults with primary malignant glioma: The Brain Tumor Center at Duke. Cancer. 1999; 85(5):1160-1165. (Pubitemid 29115597)
15. Rosing H, van Zomeren DM, Doyle E, et al. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by highperformance liquid chromatographic methods. J Chromatogr B Biomed Sci Appl. 1999;727(1-2):191-203. (Pubitemid 29189291)
16. Erlanger DM, Kaushik T, Broshek D, Freeman J, Feldman D, Festa J. Development and validation of a Web-based screening tool for monitoring cognitive status. J Head Trauma Rehabil. 2002;17(5):458-476. (Pubitemid 35244785)
17. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
18. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88. (Pubitemid 36422560)
19. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461. (Pubitemid 351597795)
20. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63(3):535-537. (Pubitemid 39031388)
21. McGirt MJ, Bulsara KR, Cummings TJ, et al. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg. 2003;98(1):14-20. (Pubitemid 36050442)
22. Roldan GB, Scott JN, McIntyre JB, et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci. 2009;36(5):617-622.
23. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl. 2003;88:105-111.
24. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3(12):1362-1368. (Pubitemid 28011036)
25. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convectionenhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery. 2005;56(6):1243-1252. (Pubitemid 40770440)
26. Popperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32(9): 1018-1025. (Pubitemid 41339276)
27. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res. 2000;6(6): 2157-2165. (Pubitemid 30399180)
28. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003;65(1):27-35. (Pubitemid 37441312)
29. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54(4):479-487. (Pubitemid 37176543)
30. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl. 2003;88:93-103.
31. Yang W, Barth RF, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot. 2004;61(5):981-985. (Pubitemid 39092651)
32. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J Clin Oncol. 2007;25(16):2306-2312.